Published: February 9, 2022

InSphero Further Strengthens Scientific Advisory Board for Liver Diseases by Appointing Professor Nikolai Naoumov

New SAB member Nikolai Naoumov brings rich experience and expertise in liver disease, and pharma drug development, as well as a keen interest in 3D in vitro technologies

Schlieren, Switzerland – February 9, 2022 - InSphero AG, the pioneer in 3D cell-based assay and organ-on-chip technology, today announced the strengthening of its Scientific Advisory Board (SAB) with the appointment of Professor Nikolai Naoumov, MD PhD.

“We are pleased to welcome this distinguished researcher to our SAB,” says InSphero VP Francisco Verdeguer, PhD. “Nikolai’s diverse expertise in liver diseases will provide invaluable insight as we continuously advance our tailored drug development efforts at the forefront of preclinical NASH research.  Visionary science has always been a driving force for InSphero’s advanced and screenable spheroid models in drug discovery and safety. Nikolai will not only guide us but also serve as a sounding board to challenge us and bring added value to our collaborative research partnerships with leading pharma and biotech organizations.”

Prof. Nikolai Naoumov is a distinguished physician-scientist with a professional career spanning academia, clinical care, and drug development. He is a Fellow of both the Royal College of Physicians (London) and the Royal College of Pathologists (UK). His research has integrated immunology, molecular biology, and translational medicine in elucidating virus-host interactions and mechanisms of liver injury. Nikolai has led research teams at the Medical Academy Sofia, King’s College Institute of Liver Studies in London, and subsequently as Professor of Hepatology at University College London.

Most recently, Prof. Naoumov expanded his contributions to medical science and clinical hepatology as Global Head, Therapeutic Area Hepatology, and Transplantation at Novartis. In parallel, he continued contributing to liver research and education as Honorary Professor of Hepatology at UCL, Scientific Advisor to the Foundation for Liver Research in the UK, and a board member of the Liver Foundation in Switzerland.

Professor Nikolai Naoumov says, “NASH is a complex disease with pathobiology involving multiple pathways and heterogenous patient population. The pathogenesis of NASH is not fully understood, and no therapies have yet been approved. In part, this is due to a lack of reliable and predictive preclinical models. I am excited for the opportunity to guide the NASH model development with an innovative company such as InSphero.”

For more information about our members, please see the InSphero Leadership Team.

Other News

Dr. Madhu Nag appointed to SLAS board of directors from January 1, 2025
News

InSphero CSO Dr. Madhu Nag Appointed to SLAS Board of Directors

InSphero is proud to announce that Chief Scientific Officer, Dr. Madhu Nag, has been appointed as a member of the Society for Laboratory Automation and Screening (SLAS) Board of Directors, serving a three-year term starting January 1, 2025. Dr. Nag will also take on the role of Board Secretary.

Read More »
Scroll to Top

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource